In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 102029-44-7, name is (R)-4-Benzyl-2-oxazolidinone, introducing its new discovery. COA of Formula: C10H11NO2
The design, synthesis, and pharmacological evaluation of L-734,217, a potent, low-molecular weight, orally active fibrinogen receptor antagonist, is reported.A strategy for producing low-molecular weight inhibitors from the peptide c-<(Ac)CRGDC>A, previously reported from these laboratories, is outlined.This strategy combines a retrodesign analysis of the conformationally defined cyclic peptide.A with stereochemical information present in the arginine-glycine-aspartic acid (RGD) tripeptide sequence, culminating with the discovery of L-734,217.L-734,217 inhibited the aggregation of human, dog, and chimpanzee platelets at concentrations below 100 nM and was found to be >15000-fold less effective at inhibiting the attachment of human umbilical vein endothelial cells to fibrinogen, fibronectin, and vitronectin than it was at inhibiting the aggregation of platelets.L-734,217 showed significant ex vivo antiplatelet activity following oral administration in dogs and chimpanzees at doses of 1.0 and 2.0 mg/kg, respectively, and has been selected as a clinical candidate for development as an antithrombotic agent.
We’ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 102029-44-7, and how the biochemistry of the body works.COA of Formula: C10H11NO2
Reference：
Oxazolidine – Wikipedia,
Oxazolidine | C3H1805NO – PubChem